Corvel Corp (CRVL)
CorVel Corp (CRVL) is a provider of risk management and healthcare solutions, including claims management, medical networks, and utilization review services. The company focuses on delivering technology-driven services to insurance companies, employers, and government entities to improve healthcare outcomes and control costs. It leverages data analytics and a network of healthcare providers to streamline claims processing and manage risk effectively.
Company News
CorVel Corporation announced a three-for-one forward stock split, effective December 24, 2024. The additional shares will be distributed on the same date, and trading is expected to begin on a post-split basis on December 26, 2024.
CORXEL, a biotech company, has acquired the worldwide (excluding Greater China) rights to CX11, an oral small molecule GLP-1 receptor agonist, for the treatment of obesity and diabetes. CX11 has shown promising results in a Phase 2 clinical trial conducted in China and CORXEL plans to initiate a global Phase 2 study in 2025.
Corstar Holdings Inc, a significant shareholder in Corvel Corp, has sold over $12.9 million worth of Corvel Corp shares between July 12 and July 16. The transactions were made pursuant to a Rule 10b5-1 trading plan.
A business might be considered boring, but a solid operator can make owners of its stock a lot of money while flying under the radar.
CRVL earnings call for the period ending June 30, 2021.